Henry Schein (NASDAQ:HSIC) issued an update on its FY18 earnings guidance on Monday morning. The company provided earnings per share guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.11.

HSIC opened at $79.80 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 1.44 and a debt-to-equity ratio of 0.34. The company has a market cap of $12.36 billion, a price-to-earnings ratio of 22.17, a P/E/G ratio of 1.91 and a beta of 1.00. Henry Schein has a 52 week low of $62.56 and a 52 week high of $89.75.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Monday, August 6th. The company reported $1.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.01 by $0.03. The firm had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.31 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 EPS. equities research analysts expect that Henry Schein will post 4.1 earnings per share for the current fiscal year.

Several equities analysts have issued reports on HSIC shares. TheStreet upgraded Henry Schein from a c rating to a b- rating in a research report on Monday, May 14th. Zacks Investment Research upgraded Henry Schein from a hold rating to a buy rating and set a $85.00 target price on the stock in a research report on Tuesday, July 10th. BidaskClub upgraded Henry Schein from a hold rating to a buy rating in a research report on Wednesday, June 13th. Northcoast Research set a $102.00 target price on Henry Schein and gave the stock a buy rating in a research report on Tuesday, April 24th. Finally, Deutsche Bank upped their price target on Henry Schein from $79.00 to $82.00 and gave the stock a buy rating in a report on Tuesday, April 24th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $84.11.

In other Henry Schein news, EVP Mark E. Mlotek sold 10,359 shares of the stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $72.73, for a total transaction of $753,410.07. Following the transaction, the executive vice president now owns 79,506 shares of the company’s stock, valued at approximately $5,782,471.38. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Paul Brons sold 4,822 shares of the stock in a transaction on Monday, June 11th. The stock was sold at an average price of $72.93, for a total value of $351,668.46. Following the transaction, the director now directly owns 20,889 shares in the company, valued at approximately $1,523,434.77. The disclosure for this sale can be found here. 1.15% of the stock is currently owned by corporate insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.